Tendon injuries can be seen in every age group, and are an important public health problem because of the significant morbidities they cause. The results of treatment may not always be optimal, despite many different surgical or non-surgical treatment options avaliable. Recently developed biological augmentation strategies can be grouped in two; as cytokine-growth factor related and cell-based methods. Most widely used growth factor based biological method is the platelet-rich plasma (PRP); but members of the transforming growth factor-β (TGF-β) family, fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) have also shown promising results in pre-clinical studies. Cellbased methods mostly utilize mesenchymal stem cells (MSC) obtained from either adipose tissue or bone marrow. More recently, induced pluripotent stem cells (iPSC) and stem-cell derived exosomes have been developed as the novelties in this field of research. Despite all these exciting developments, the lack of standardization in conducting and reporting these studies are remarkable. More effort must be taken in order to achieve the use of a common language in this field. Current literature on biological augments is evolving at a fast pace, and cthe near future may bring more therapeutic options to the orthopedic surgery daily practice.